GNRH1 and Familial prostate cancer: For example, we found that bicalutamide, an anti-androgen, was associated with risk of death, likely due to that bicalutamide was combined with GnRH antagonist/agonist in men with particularly aggressive prostate cancer in order to obtain maximal androgen blockade.